cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ocugen Inc
137 own
88 watching
Current Price
$1.26
$-0.07
(-5.26%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
94.18M
52-Week High
52-Week High
2.10500
52-Week Low
52-Week Low
0.34500
Average Volume
Average Volume
6.14M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization94.18M
icon52-Week High2.10500
icon52-Week Low0.34500
iconAverage Volume6.14M
iconDividend Yield--
iconP/E Ratio--
What does the Ocugen Inc do?
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Read More
How much money does Ocugen Inc make?
News & Events about Ocugen Inc.
Globe Newswire
12 months ago
MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Zolmax
1 year ago
Ocugen, Inc. (NASDAQ:OCGN Get Rating) Director Junge Zhang purchased 200,278 shares of the companys stock in a transaction on Wednesday, June 14th. The stock was bought at an average price of $0.50 per share, for a total transaction of $100,139.00. Following the completion of the purchase, the ...
Globe Newswire
1 year ago
Conference Call and Webcast Today at 8:30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)Received Orphan Drug Designation (ODD) from the FDA for OCU410ST for the ...
Globe Newswire
1 year ago
MALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live ...
Globe Newswire
1 year ago
Favorable safety and tolerability profile related to OCU400 investigational product candidateInitial clinical data from low and medium dose cohorts indicates positive trend in Multi-luminance mobility testing and Best-Corrected Visual Acuity scores for OCU400 treated eyes71.4% (5/7) of OCU400 ...
Frequently Asked Questions
Frequently Asked Questions
What is Ocugen Inc share price today?
plus_minus_icon
Can Indians buy Ocugen Inc shares?
plus_minus_icon
How can I buy Ocugen Inc shares from India?
plus_minus_icon
Can Fractional shares of Ocugen Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Ocugen Inc stocks?
plus_minus_icon
What is today’s traded volume of Ocugen Inc?
plus_minus_icon
What is today’s market capitalisation of Ocugen Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Ocugen Inc?
plus_minus_icon
What percentage is Ocugen Inc down from its 52-Week High?
plus_minus_icon
What percentage is Ocugen Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.26
$-0.07
(-5.26%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00